https://ascopubs.org/doi/full/10.1200/JCO.18.01295 Vol. 37, No. 13, May 1, 2019 pages 1062-9
What an interesting read. The control arm of METASTATIC pancreatic cancer using FOLFIRINOX had a median survival of 14.4 months.
Not looking for Oncosil's argument that median survival would've been 9-11 months for LOCAL pancreatic cancer had they incorporated a control arm in the trial design.
I wonder if the tome Oncosil wrote included that one.
OSL Price at posting:
9.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)